major adverse cardiovascular events

Inpatient Rehabilitation and Major Adverse Cardiovascular Events After Ischemic Stroke: Clinical Implications and Evidence Synthesis

By MedXY 09/19/2026

Postacute discharge to inpatient rehabilitation facilities (IRF) after acute ischemic stroke (AIS) is associated with a reduced 1-year risk of major adverse cardiovascular events (MACE) compared to discharge to home or skilled nursing facilities (SNF).

Cardiology Hematology-Oncology news

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data

By MedXY 09/19/2026

Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitoring and preventive strategies.

Cardiology news

Sustained Cardiovascular Protection With Evolocumab in Patients Without Prior MI or Stroke: Insights From the VESALIUS-CV Trial

By MedXY 08/30/2026

Evolocumab significantly reduces first and subsequent major adverse cardiovascular events in high-risk patients without prior myocardial infarction or stroke, affirming the benefit of intensive LDL-C lowering for cumulative cardiovascular risk reduction.

Cardiology Diabetes & Endocrinology news

Parathyroidectomy Significantly Lowers Cardiovascular Risk in Primary Hyperparathyroidism: Insights from a Population-Wide Target Trial Emulation

By MedXY 08/24/2026

This population-wide study demonstrates that parathyroidectomy in primary hyperparathyroidism reduces major adverse cardiovascular events risk, particularly in patients with higher serum calcium levels.

Cardiology Hematology-Oncology news

Assessing Cardiovascular Risks Associated with Bruton’s Tyrosine Kinase Inhibitors: Insights from a Meta-Analysis of Phase 3 Trials

By MedXY 08/24/2026

This meta-analysis of 17 Phase 3 RCTs reveals that BTK inhibitors, primarily ibrutinib, increase the risk of non-fatal ischemic cardiovascular events in patients with B-cell malignancies, highlighting important safety considerations.

Cardiology news Public Health

Updated COVID-19 Vaccination and Cardiovascular Protection: What a Large VA Study Found in 2024-2025

By MedXY 06/19/2026

In over 1 million US veterans, the 2024-2025 COVID-19 vaccine was associated with fewer COVID-19-related cardiovascular events, with the strongest benefit in adults over 75 and those with comorbidities.

Cardiology Diabetes & Endocrinology news

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

By MedXY 10/19/2025

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes status.

Allergy & Immunology Cardiology Clinical Updates Dermatology news Specialties

Interleukin-17 Inhibitors and Cardiovascular Risk: Evaluating Early Major Adverse Cardiovascular Events

By MedXY 09/03/2025

A national database study finds no significant increase in early major adverse cardiovascular events (MACEs) after starting IL-17 inhibitors in psoriasis and related diseases, although a modest risk cannot be excluded.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.